AbbVie Reports Positive Phase 3 Results for Lutikizumab in Hidradenitis Suppurativa

AbbVie announced positive topline results from its Phase 3 INTREPID study of lutikizumab for moderate to severe hidradenitis suppurativa in adults and adolescents. The investigational dual-variable-domain interleukin antagonist met its primary endpoint, showing significantly higher response rates and improvements in HS-related pain and flares compared to placebo. This development suggests a potential new treatment option for patients with this chronic inflammatory skin condition.